All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @weightdoc on TikTok · 61s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @weightdoc's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Constipation on a GLP1 is no joke.
  2. 0:02It is one of the most common side effects
  3. 0:04that people will experience.
  4. 0:05And I prepare people just to expect it
  5. 0:08because it is so common, most people have at least
  6. 0:11some degree of constipation.
  7. 0:12And it doesn't always improve with time.
  8. 0:14Many GLP1 side effects improve the longer
  9. 0:17that you are on the medication,
  10. 0:18but constipation is not always one of them.
  11. 0:21That being said, it's usually not severe.
  12. 0:23There's a lot that we can do to manage it.
  13. 0:25And it is almost never a reason
  14. 0:27that we have to stop the medication.
  15. 0:28The key is staying on top of it.
  16. 0:31Do not let it get horrendous.
  17. 0:32Don't wait until you have bleeding hemorrhoids
  18. 0:34to go talk to your doctor about it.
  19. 0:36There's no need to let it get that bad every day.
  20. 0:39Think about water, movement.
  21. 0:41Exercise helps stimulate the bowels to move.
  22. 0:44Whatever you do, don't forget about fiber.
  23. 0:46Incorporate more fiber-rich foods like apples, beans, oats,
  24. 0:50add a psyllium husk supplement if needed.
  25. 0:52A step beyond that would be over-the-counter medications
  26. 0:55like Miralax, magnesium citrate,
  27. 0:57and even oralistat, and some people do need that.

@weightdoc's constipation advice is spot on

Dr Jennah | WeightDoc

TikTok creator

22.0K viewsWatch on TikTok

Quick answer

Constipation affects roughly 17 to 24 percent of patients on GLP-1 receptor agonists depending on the drug and dose, driven by reduced gut motility that may not resolve with continued use. Management appropriately starts with dietary fiber and hydration, progresses to osmotic laxatives like polyethylene glycol, and in refractory cases may require prescription prokinetic or secretagogue agents. The creator's reference to 'oralistat' as a constipation treatment appears to be a clinical error, as orlistat is a weight-loss drug with a GI side effect profile that includes diarrhea, not constipation relief.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @weightdoc's constipation advice is spot on, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@weightdoc's constipation advice is spot on is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@weightdoc's constipation advice is spot on" from Dr Jennah | WeightDoc. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Constipation affects roughly 17 to 24 percent of patients on GLP-1 receptor agonists depending on the drug and dose, driven by reduced gut motility that may not resolve with continued use.

The reason this review is not generic is the source wording and the canonical claim label "glp1 unpopular opinion staying regular is a form of self care." In this clip, the useful excerpt is: "Constipation on a GLP1 is no joke." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Unlike nausea, constipation on GLP-1 drugs does not reliably resolve with continued use because slowed colonic transit is driven by peripheral GLP-1 receptor activity, not just central adaptation.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Constipation affects roughly 17 to 24 percent of patients on GLP-1 receptor agonists depending on the drug and dose, driven by reduced gut motility that may not resolve with continued use.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Constipation affects roughly 17 to 24 percent of patients on GLP-1 receptor agonists depending on the drug and dose, driven by reduced gut motility that may not resolve with continued use. Management appropriately starts with dietary fiber and hydration, progresses to osmotic laxatives like polyethylene glycol, and in refractory cases may require prescription prokinetic or secretagogue agents. The creator's reference to 'oralistat' as a constipation treatment appears to be a clinical error, as orlistat is a weight-loss drug with a GI side effect profile that includes diarrhea, not constipation relief.
  • STEP 1 trial data shows constipation in roughly 24 percent of semaglutide users, making it the second most common GI side effect after nausea (Wilding et al., 2021, NEJM).
  • Unlike nausea, constipation on GLP-1 drugs does not reliably resolve with continued use because slowed colonic transit is driven by peripheral GLP-1 receptor activity, not just central adaptation.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • STEP 1 trial data shows constipation in roughly 24 percent of semaglutide users, making it the second most common GI side effect after nausea (Wilding et al., 2021, NEJM).
  • Unlike nausea, constipation on GLP-1 drugs does not reliably resolve with continued use because slowed colonic transit is driven by peripheral GLP-1 receptor activity, not just central adaptation.
  • Average U.S. fiber intake is about 15 grams per day against a recommended 25 to 38 grams, and that gap likely widens on GLP-1 drugs since patients eat less overall (USDA Dietary Guidelines 2020-2025).
  • Polyethylene glycol (Miralax) is considered first-line for functional constipation and is appropriate for regular use; magnesium citrate is better suited for occasional acute relief.
  • The creator's reference to 'oralistat' for constipation appears to be a clinical error. Orlistat causes diarrhea and oily stools and should not be used to treat constipation.
  • If dietary fiber, hydration, and OTC osmotic laxatives are insufficient, prescription options like linaclotide or prucalopride exist and should be discussed with a prescriber, not self-selected from a social media video.
  • Bleeding hemorrhoids are a signal to contact your doctor, not a baseline expectation. The creator's advice to intervene early, before things become severe, is clinically appropriate and consistent with standard guidance.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @weightdoc actually say?

The creator made a cluster of specific, practical claims: constipation is one of the most common GLP-1 side effects, it often does not improve with time the way nausea does, it rarely forces people to stop the medication, and the management ladder runs from water and movement up through fiber, psyllium husk, Miralax, magnesium citrate, and something called "oralistat." That last one deserves a flag we will get to shortly.

The framing was refreshingly honest. Rather than downplaying a known side effect, the creator told patients to get ahead of it. "Do not let it get horrendous," they said. "Don't wait until you have bleeding hemorrhoids to go talk to your doctor about it." That is a clinically responsible message, and it is the kind of thing patients on semaglutide or tirzepatide genuinely need to hear before week one, not after week eight.

Does the science back this up?

Yes, mostly. Constipation as a GLP-1 side effect is well-documented and underappreciated in casual conversations about these drugs. The clinical trial data is fairly consistent here.

In the SURMOUNT-1 trial of tirzepatide (Jastreboff et al., 2022, New England Journal of Medicine), constipation was reported in roughly 17 to 20 percent of participants at the higher doses, making it the second most common gastrointestinal complaint after nausea. STEP 1 trial data for semaglutide (Wilding et al., 2021, NEJM) showed similar patterns, with constipation affecting around 24 percent of the semaglutide group versus about 11 percent of placebo.

The claim that constipation does not always resolve with continued use is also supported. GLP-1 drugs slow gastric emptying and reduce gut motility through central and peripheral mechanisms. Unlike nausea, which tends to attenuate as the gut adapts to the drug, slowed colonic transit can persist. A 2023 review by Sodhi et al. in JAMA raised questions about long-term GI outcomes with these drugs, though that study had significant methodological debates attached to it. The basic physiology still supports the creator's point.

What did they get wrong (or right)?

Let us start with what they got right. The management hierarchy they described, hydration, movement, dietary fiber, psyllium husk, then osmotic laxatives, is essentially textbook and appropriate. Psyllium husk has solid evidence behind it for constipation generally (McRorie, 2015, Nutrition Today). Polyethylene glycol (Miralax) is first-line for functional constipation and is reasonable to use here. Magnesium citrate works as an osmotic laxative, though it is a bit more aggressive and typically used for acute relief rather than daily management.

Now the problem. The creator recommended "oralistat" as a step in the constipation management ladder. This appears to be a mispronunciation or mix-up. Orlistat is a lipase inhibitor used for weight loss that famously causes oily stools and diarrhea, not constipation relief. It has no place in a constipation management protocol and could actually worsen GI distress in someone already dealing with GLP-1 side effects. The intended drug was almost certainly Linzess (linaclotide) or possibly Motegrity (prucalopride), both of which are prescription options for chronic constipation. This is a meaningful clinical error that patients should not act on.

What should you actually know?

If you are on a GLP-1 medication and dealing with constipation, the creator's core advice is sound: do not wait it out passively, and do not assume it will go away on its own. The physiological reasons constipation persists on these drugs are real. GLP-1 receptors exist throughout the gut, and slowing motility is not a bug that disappears after a few weeks of dose titration for everyone.

Start with the basics before reaching for laxatives. Fiber intake in the U.S. averages around 15 grams per day against a recommended 25 to 38 grams (USDA Dietary Guidelines, 2020-2025). Most people on GLP-1 drugs are eating less overall, which means fiber intake likely drops further. A psyllium husk supplement is a low-risk, low-cost way to close that gap. If you need an OTC laxative, polyethylene glycol is well-tolerated for regular use. Magnesium citrate is fine for occasional use but not a daily solution.

Do not self-prescribe based on anything you hear described as "oralistat" for constipation. That recommendation does not hold up. Talk to your prescriber if fiber and Miralax are not enough, because there are legitimate prescription options available.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr Jennah | WeightDoc · TikTok creator

22.0K views on this video

Unpopular opinion: staying regular is a form of self-care 💩 #constipation #guthealth #fiber #hemorrhoids #TikTokCreatorSearchInsightsIncentive

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about step 1 trial data shows constipation in roughly 24 percent?

STEP 1 trial data shows constipation in roughly 24 percent of semaglutide users, making it the second most common GI side effect after nausea (Wilding et al., 2021, NEJM).

What does the video say about unlike nausea, constipation on glp-1 drugs does not reliably resolve?

Unlike nausea, constipation on GLP-1 drugs does not reliably resolve with continued use because slowed colonic transit is driven by peripheral GLP-1 receptor activity, not just central adaptation.

What does the video say about average u.s. fiber intake?

Average U.S. fiber intake is about 15 grams per day against a recommended 25 to 38 grams, and that gap likely widens on GLP-1 drugs since patients eat less overall (USDA Dietary Guidelines 2020-2025).

What does the video say about polyethylene glycol (miralax)?

Polyethylene glycol (Miralax) is considered first-line for functional constipation and is appropriate for regular use; magnesium citrate is better suited for occasional acute relief.

What does the video say about the creator's reference to 'oralistat' for constipation appears to be?

The creator's reference to 'oralistat' for constipation appears to be a clinical error. Orlistat causes diarrhea and oily stools and should not be used to treat constipation.

What does the video say about if dietary fiber, hydration,?

If dietary fiber, hydration, and OTC osmotic laxatives are insufficient, prescription options like linaclotide or prucalopride exist and should be discussed with a prescriber, not self-selected from a social media video.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dr Jennah | WeightDoc, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.